Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Medical Devices & Mechanical Engineering
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Medytox Inc. currently manages 4 pending office actions within the Biotechnology & Pharmaceuticals technology area. This workload is distributed across 4 distinct examiners, indicating a lack of examiner concentration for the portfolio. The prosecution activity spans 4 distinct art units, which suggests the company's intellectual property covers diverse technical sub-sectors.
MONSHIPOURI, MARYAM is identified as the busiest examiner, though they are responsible for only 1 pending office action. The distribution of 4 pending office actions among 4 distinct examiners and 4 distinct art units reflects a fragmented prosecution landscape. Practitioners should prepare for varied examination styles across these 4 distinct art units.
This distribution ensures that no individual examiner or art unit dominates the current pending matters, requiring a broad strategy for the 4 pending office actions. Each of the 4 distinct examiners will likely apply unique interpretations to the Biotechnology & Pharmaceuticals claims. The 1 to 1 ratio of actions to examiners necessitates individualized attention for each filing.
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| §102 only | 1 (25%) |
| Double-patenting + other | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MONSHIPOURI, MARYAM | 1 | 79.1% | +37.5% |
| BOWERS, ERIN M | 1 | 54.7% | +10.6% |
| ALLEN, MARIANNE P | 1 | 60.1% | +18.2% |
| STIGELL, THEODORE J | 1 | 78.3% | +14.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18023120 | ANTI-VEGF HEXAMERIC ANTIBODY AND COMPOSITION COMPRISING SAME | ALLEN, MARIANNE P | 76d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18709913 | BOTULINUM NEUROTOXIN COMPOSITION | MONSHIPOURI, MARYAM | 15d overdue |
| 17995428 | BOTULINUM TOXIN PRE-FILLED INJECTABLE FORMULATION THAT FACILITATES DISCHARGE RATE CONTROL AND IS STABLE | STIGELL, THEODORE J | 6d |
| 18023120 | ANTI-VEGF HEXAMERIC ANTIBODY AND COMPOSITION COMPRISING SAME | ALLEN, MARIANNE P | 76d |
| 18574838 | RECOMBINANT BOTULINUM TOXIN TYPE A LIGHT CHAIN, RECOMBINANT BOTULINUM TOXIN, AND COMPOSITION, USE, AND METHOD THEREOF | BOWERS, ERIN M | — |
| Art Unit | Apps |
|---|---|
| 1651 | 1 |
| 1653 | 1 |
| 1647 | 1 |
| 3783 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18709913 | BOTULINUM NEUROTOXIN COMPOSITION | MONSHIPOURI, MARYAM | 1651 | §112DP | Final Rejection | 15d overdue | Pending | May 14, 2024 |
| 18574838 | RECOMBINANT BOTULINUM TOXIN TYPE A LIGHT CHAIN, RECOMBINANT BOTULINUM TOXIN, AND COMPOSITION, USE, AND METHOD THEREOF | BOWERS, ERIN M | 1653 | §102 | Non-Final OA | — | Pending | Dec 28, 2023 |
| 18023120 | ANTI-VEGF HEXAMERIC ANTIBODY AND COMPOSITION COMPRISING SAME | ALLEN, MARIANNE P | 1647 | §102§103§112 | Final Rejection | 76d | Pending | Feb 24, 2023 |
| 17995428 | BOTULINUM TOXIN PRE-FILLED INJECTABLE FORMULATION THAT FACILITATES DISCHARGE RATE CONTROL AND IS STABLE | STIGELL, THEODORE J | 3783 | §103 | Non-Final OA | 6d | Pending | Oct 04, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial